Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
mutations render vaccs ineffective
in a year or less?
https://interestingengineering.com/covid-19-mutations-could-make-vaccines-ineffective-in-a-year-or-less
May 17 ... that's MY birthday!
What is the difference between TGLO and a SPAC ?
J&J filed for emergency use for their covid19 vaccine. Coudldn't IPIX file for emergency use of Brilacidin?
As long as petemantx concurs, sure.
Exactly.
With all due respect to petemantx
But I wanted to tighten up his passages a bit, and add some spacing and emphases.
(Annoyingly, iHub doesn't allow indenting for paragraphs)
"
The current clinical trial for Brilacidin for Covid-19 is critical to the success of IPIX.
Brilacidin is different from EVERY other drug going through trials today. It is likely different from any drug EVER to go through trials.
We are sitting on a gold mine with IPIX.
To wit:
1. Brilacidin was invented by Dr. William DeGrado.
Dr. Degrado has published over 400 papers, won about every medical award that can be won, and is the leading authority on the new arm of medicine he created: Defensin mimetics.
He currently runs his own lab for study of (and only for the study of) defensin mimetics at the acclaimed UCSF, a public research facility associated with the University of California system.
UCSF has no undergraduate programs. Every student there works on advanced degrees and is only accepted to work on a specific program.
So all of Dr. DeGrado's graduates become proponents of his arm of medicine and further exploration thereof.
Dr. DeGrado is not a medical doctor--he is a PhD specializing in pharmaceutical chemistry, which was key to conceptualizing the small molecule that would become Brilacidin.
2. Brilacidin, developed around 2002 through hands-on lab work, was refined and improved in 6 years of computation by the supercomputer Big Ben in Pittsburgh. The next best thing to A.I., Big Ben ramped up Brilacidin's benefits while reducing or eliminating weaknesses and side effects.
Compared to many drugs developed in labs, this puts Brilacidin light years ahead of many other drugs developed in labs.
3. Brilacidin has never failed a clinical trial, and it has gone through quite a few.
It is anti-viral, anti-bacterial, anti-fungal and an anti-inflammatory, and possesses unique immuno-modulating properties.
ALL of that kills or helps kill the Covid19 virus.
In trials with 400 patients Brilacidin was well-tolerated with no discernible side effects, almost unheard of in the pharmaceutical industry (just read or listen to advertisements for other drugs--in many cases they list side effects that seem as bad as the sicknesses they treat).
4. Brilacidin kills viruses in a novel way against which viruses cannot develop resistance.
Note that Brilacidin actively KILLS the Covid19 virus, a feature very few (if any) competing therapies can claim.
5. During testing of Brilacidin at government-run RBLs (Regional Bio Labs), IPIX had no input as to the conduct of the tests or in interpretation of results.
All data was derived and published by those RBLs.
Brilacidin showed a Selectivity Index (SI) of 426.
SI evaluates how well the results of in-vitro testing (in a lab cell culture) are replicated in human subjects.
Anything over 100 is considered good.
The much-touted Remsdesivir shows an SI of only about 129.
It seems Brilacidin should have a lock on being as effective in human patients as it is in human tissue in the lab.
(To refresh our memory of human tissue results: Brilacidin killed 97% of the Covid19 virus in lung tissue within a few hours, and 85% in kidney tissue -- again, within a few hours).
The IV solution being administered in the current trial (I believe for about an hour) should boost those percentages in-vivo (in the patient), since the IV maintains concentrations of Brilacidin for an extended time.
6. Brilacidin is made from common ingredients, does not require special handling, is very cost effective compared to other methods, and is currently being developed for easier delivery into the body as a nasal spray, or with nebulizers (as a mist inhaled into the lungs).
7. Brilacidin was shown to be so effective in testing that one of the RBLs requested funding for a PANCORONA investigation--it appeared that Brilacidin might prove effective against ALL types of corona viruses, including other flu-like variants and herpes, among others.
8. Brilacidin has yet to meet a bacteria or virus it can't kill.
All of the above is derived from non-IPIX sources.
------------------------------------------------------
All shareholders of IPIX should at least be getting a hint that what we own is extremely special.
Every shareholder should however make up their own minds as to when to sell. But be aware that, though currently a penny stock, IPIX's products may lead to generational wealth for those who took a bet on this company early.
I consider 45 cents a share to still be early--indeed, still extremely early. I hate to think some shareholders will be bamboozled into selling much too soon, and lose out on a true "golden goose" stock that comes along but a few times in a lifetime.
"
There's that vexatious term "soon" again.
I'm getting soonaphobia.
OMG !!! Is it happening ??? At last??
This board is for Voyager Therapeutics.
Go post on the VYGVF board.
I know what a virus is. But what's a "viren"?
try waiting for covid-delayed phase III results from Cel-Sci
The 'Smartest Man in the Room' has Joined Sidney Powell's Team
Andrea Widburg, American Thinker
In her Georgia complaint, Sidney Powell included the declaration of Navid Keshavarz-Nia, an expert witness who stated under oath that there was massive computer fraud in the 2020 election, all of it intended to secure a victory for Joe Biden.
Dr. Kershavarz-Nia's name may not mean a lot to you, but it's one of the weightiest names in the world when it comes to sniffing out cyber-security problems.
We know how important Dr. Kershavarz-Nia is because, just two and a half months ago, the New York Times ran one of its Sunday long-form articles about a massive, multi-million-dollar fraud that a talented grifter ran against the American intelligence and military communities.
Dr. Kershavarz-Nia is one of the few people who comes off looking good:
Navid Keshavarz-Nia, those who worked with him said, "was always the smartest person in the room." In doing cybersecurity and technical counterintelligence work for the C.I.A., N.S.A. and F.B.I., he had spent decades connecting top-secret dots. After several months of working with Mr. Courtney, he began connecting those dots too. He did not like where they led.
Not only does Dr. Kershavarz-Nia have an innate intelligence, but he's also got extraordinary academic and practical skills in cyber-fraud detection and analysis.
The reason we know about his qualifications is that it takes seven paragraphs for him to list them in the declaration he signed to support the Georgia complaint.
His qualifications include a B.A., M.A., and Ph.D. in various areas of electrical and computer engineering. In addition, "I have advanced trained from the Defense Intelligence Agency (DIA), Central Intelligence Agency (CIA), National Security Agency (NSA), DHS office of Intelligence & Analysis (I&A) and Massachusetts Institution of Technology (MIT)."
Professionally, Dr. Kershavarz-Nia has spent his career as a cyber-security engineer. "My experience," he attests," spans 35 years performing technical assessment, mathematical modeling, cyber-attack pattern analysis, and security intelligence[.]"
I will not belabor the point. Take it as given that Dr. Kershavarz-Nia may know more about cyber-security than anyone else in America.
So what does the brilliant Dr. Kershavarz-Nia have to say? This:
1. Hammer and Scorecard is real, not a hoax (as Democrats allege), and both are used to manipulate election outcomes.
2. Dominion, ES&S, Scytl, and Smartmatic are all vulnerable to fraud and vote manipulation — and the mainstream media reported on these vulnerabilities in the past.
3. Dominion has been used in other countries to "forge election results."
4. Dominion's corporate structure is deliberately confusing to hide relationships with Venezuela, China, and Cuba.
5. Dominion machines are easily hackable.
6. Dominion memory cards with cryptographic key access to the systems were stolen in 2019.
Although he had no access to the machines, Dr. Kershavarz has looked at available data about the election and the vote results. Based on that information, he concluded
1. The counts in the disputed states (Pennsylvania, Wisconsin, Michigan, Arizona, Nevada, and Georgia) show electronic manipulation.
2. The simultaneous decision in Pennsylvania, Wisconsin, Arizona, Nevada, and Georgia to pretend to halt counting votes was unprecedented and demonstrated a coordinated effort to collude toward desired results. [Emphasis in the original.]
3. One to two percent of votes were forged in Biden's favor.
4. Optical scanners were set to accept unverified, un-validated ballots.
5. The scanners failed to keep records for audits, an outcome that must have been deliberately programmed.
6. The stolen cryptographic key, which applied to all voting systems, was used to alter vote counts.
7. The favorable votes pouring in after hours for Biden could not be accounted for by a Democrat preference for mailed in ballots. They demonstrated manipulation.
For example, in Pennsylvania, it was physically impossible to feed 400,000 ballots into the machines within 2–3 hours.
8. Dominion used Chinese parts, and there's reason to believe that China, Venezuela, Cuba interfered in the election.
9. There was a Hammer and Scorecard cyber-attack that altered votes in the battleground states, and then forwarded the results to Scytl servers in Frankfurt, Germany, to avoid detection.
10. The systems failed to produce any auditable results.
Based on the above findings, Dr. Keshavarz-Nia concluded with "high confidence that the election 2020 data were altered in all battleground states resulting in a [sic] hundreds of thousands of votes that were cast for President Trump to be transferred [sic] to Vice President Biden."
This is going to be tough evidence for Democrats to counter. Back when the naïve Democrats thought Trump would be the one to commit fraud, they held congressional hearings and wrote articles about the voting machines' vulnerability. And with the New York Times touting Dr. Keshavarz-Nia's brilliance and his ability to sniff out fraud, they'll struggle to [say] that he's not a reliable expert.
Things are getting fun.
"The extraction of these resources adversely affects Americans health and should be left in the ground where it is safe." [Emphasis added.]
If they are to be left in the ground, regarded no better than toxic waste, then why still call them "resources"?
About as dumb as AOC. But I don't think AOC would be so shy.
My assumptions too from the start.
One thing I can't dig up, though: What happens to a capital pool company like Bluewater when they don't execute a RM in time?
Does it just evaporate? Can they apply for an extension? Can they still pursue an RM but without being able to trade on an exchange? Inquiring minds want to know.
Whoa. "Reason: Failure to Complete a Qualifying Transaction within 24 Months Of Listing"
Trading halt just declared some minutes ago for Bluewater Acquisition?
I'm all for patients living longer. But if they're going to outlive the investors as the investors wait for the data, I'm through.
Suppose--just suppose--one or more of the Multikine clinical trial centers, or their departments thereof involved, was hit by ransomware attack(s). Would that be considered a material event? (We'd probably already know of it though, wouldn't we?)
I think Bluewater Acquisition, as a Canadian blank-check shell (I forget the Canadian term for it), has until the end of its 2-year charter (this November I believe) to execute a reverse-merger with some private company. Otherwise it gets dissolved.
I think INVA an epic buying opportunity below $10. Indicators continue pointing downward, may dip close to $9.
"The scientists are now looking to further refine the design and chemistry of the Nano-pPAAM ... this includes combining their method with other therapies such as immunotherapy which uses the body's immune system to fight cancer."
Bingo.
In myself and mother's side of my family it hits us hard in the knuckles first, and early. Then it goes after the knees.
Always thought it curious though that it hits this or that finger first, and not any of the others for awhile. What's up with that?
Dude!
It was less than .13 when I went out to get some yard work done. I just got back in and checked how it was doing. Ha ha, BAM!
Hmmm, looks promising. Just grabbed 5500 shares at .13, what the hay, I've tangled my fortunes in far worse things. Like Hyperdynamics.
was feeling flurffy anyway
still in CVM at ~4000 sh
Then what the hell did Geert mean when he said "very very soon"?
Was something lost in translation inside his head?
A three-legged turtle.
Kinky passed away a few years ago, I believe
My eldery aunt is in an assisted living in Hattiesburg MS. They have the place locked down almost as tight as that base in The Andromeda Strain.
super what?
super what?
As I may have once mentioned before, what "very very soon" means to a scientist and what it means to a layman investor can be two very very different things.
Would a 'grassroots' "right to try" petition/application/whatever hold any water?
"507 total participants have been dosed with [intravenous] Brilacidin (aka PMX-30063)... in human clinical trials."
Then why are we--why would anyone--still fool around with Brilacidin in tissue cultures during what is, by any standard, an ongoing national emergency, with tens of thousands dead and thousands more certain yet to die?
B's Wikipedia page is in need of some serious updating
the "Wall Street daily", whatever the hell that is, is not the Wall Street Journal
too bad the FDA has no provision for expedited application for "emergency field trials".
or does it?
One thing I know for sure, whenever a scientist says "very soon", it can mean anything from one week to one year (or more).
But my w.a.g.: July 6th or 13th